Recon: Novo Nordisk to sell discounted GLP-1s at the pharmacies; FDA’s absence from international standards meetings imperils U.S. leadership

• Novo Nordisk’s obesity drug Wegovy cleared to treat MASH (STAT)
• Wall Street sees new obesity pills as priced near Wegovy and Zepbound (Reuters)
• Draft of major MAHA report calls for more education, less regulation — and offers few policies (STAT)
• RFK Jr. Is Sabotaging President Trump’s Health Legacy (Bloomberg)
• Bayer Reaches Settlement Over Seattle-Area School PCB Cases (Bloomberg)
• Sometimes Less is More: FDA Issues White Paper on Selective Safety Data Collection (FDA Law Blog)

• The FDA’s absence from international standards meetings threatens U.S. leadership (STAT)
• Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs (Bloomberg)
• UK MHRA Ready To Evolve Approach To In-House Manufactured Medtech (MedTech Insight)
• Japan To Cut Leqembi Price By 15% Following Cost Effectiveness Review (Pink Sheet)

• Health care CEOs harvest billions even as industry lags broader stock market (STAT)
• Stealth BioTherapeutics discloses FDA rejection letter in effort to rally support for rare disease drug (STAT)
• Novo Nordisk offers Ozempic at $499 per month to eligible US cash-paying customers (Reuters)
• What other health conditions are weight-loss drugs being tested for? (Reuters)
• US FDA approves Tonix Pharma's drug to manage pain related to chronic condition (Reuters)
• Genentech ends up to $2B cell therapy collab with Adaptive (Endpoints)
• Gene therapy startup Kriya Therapeutics gets $313M (Endpoints)
• Stealth resubmits ultra-rare disease drug to FDA; Boehringer's retinal deal (Endpoints)
• Updated: Reunion’s psychedelic approach in postpartum depression clears Phase 2 trial (Endpoints)
• Eli Lilly Taps High-Grade Market With Rare 40-Year Paper (Bloomberg)
• How the Moms and Dads of Patients Won Sarepta’s Drug a Reprieve (Bloomberg)

• Exclusive: Athletics-New gene tests system in disarray ahead of world championships (Reuters)
• Heart devices pace medtech’s summer funding flows (MedTech Dive)
• Philips will spend $150M to expand manufacturing for AI-enabled tech (MedTech Dive)
• Nyxoah Launches FDA-Cleared Genio System For OSA As Rival Inspire Files Patent Suit (MedTech Insight)
• Inaccurate Carbon Dioxide Readings Prompt Class I Recall Of Draeger Ventilation Filters (MedTech Insight)

• Culinary medicine pioneer David Eisenberg: ‘If you know how to make one stir-fry, you can make 1,000’ (STAT)
• Draft 'MAHA' commission report avoids pesticide crackdown feared by farm groups (Reuters)
• Artificial Dyes Are Disappearing Inside the Welch’s Fruit Snacks Factory (Bloomberg)
• FMI says it’s concerned about tariffs’ impacts on grocery prices (Food Dive)
• WK Kellogg signs legal agreement to remove artificial dyes from cereals (Food Dive)

• With U.S. funding for science at risk, a longtime advocate sees ‘light at the end of the tunnel’ (STAT)
• Former CDC Director William Foege: How public health can fight back in a time of dangerous nonsense (STAT)
• End the unchecked growth of publishing fees and the overreliance on unpaid peer review (STAT)
• Conflicts of interest among federal vaccine advisors were ‘historically low’ through 2024 (Endpoints)
• Texas Ends Measles Outbreak With No New Cases Since July (Bloomberg)